Selected Grants
Genomic Imprinting in the Development of NAFLD
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2028Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis
ResearchCo-Principal Investigator · Awarded by University of Texas - Southwestern · 2023 - 2027The Southeastern Liver Health Cohort Study
ResearchPrincipal Investigator · Awarded by North Carolina State University · 2023 - 2027Lipid Metabolite Profiles and Cardiovascular Events in Persons with HIV (PWH) who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ResearchCo-Mentor · Awarded by American College of Gastroenterology · 2024 - 2027Duke Training Grant in Digestive Diseases and Nutrition
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1988 - 2027Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialPrincipal Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with pre-cirrhotic Non-Alcoholic Steatohepatitis (NASH)
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2023 - 2026Exact Sciences ALTUS 2021-01_PRO00115210 ALTUS: Performance of a Multi-Target Hepatocellular Carcinoma (HCC) Test in Subjects with Increased Risk
Clinical TrialPrincipal Investigator · Awarded by Exact Sciences Corporation · 2024 - 2026A multidisciplinary study of biological disparities in NASH progression and response to statins to inform personalized liver cancer chemoprevention in NAFLD
ResearchPrincipal Investigator · Awarded by Mayo Clinic - Rochester · 2022 - 2025Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD) - Cost Reimbursable
Clinical TrialPrincipal Investigator · Awarded by Northwestern University · 2020 - 2025Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD) - Fixed Rate
Clinical TrialPrincipal Investigator · Awarded by Northwestern University · 2020 - 2025The Southeastern Liver Health Cohort Study
ResearchPrincipal Investigator · Awarded by North Carolina State University · 2021 - 2023Exact Sciences ALTUS
Clinical TrialPrincipal Investigator · Awarded by Exact Sciences Corporation · 2022 - 2023A multidisciplinary study of biological disparities in NASH progression and response to statins to inform personalized liver cancer chemoprevention in NAFLD
ResearchCollaborating Investigator · Awarded by Department of Defense · 2020 - 2023Is Heart Failure with Preserved Edection Fraction the Symptomatic Manifestation of Liver Disease
ResearchCollaborator · Awarded by American Heart Association · 2021 - 2022Hepatocellular Carcinoma, Epigenetics and Cadmium Exposure
ResearchPrincipal Investigator · Awarded by North Carolina State University · 2019 - 2022Genetic and Epigenetic Markers of Progressive Nonalcoholic Fatty Liver Disease
ResearchPrincipal Investigator · Awarded by American Association for the Study of Liver Diseases · 2018 - 2020Epigenetics and the Development of Nonalcoholic Fatty Liver Disease
ResearchPrincipal Investigator · Awarded by American College of Gastroenterology · 2015 - 2019Role of the Stroma in Fibrolamellar Hepatocellular Carcinoma
ResearchInvestigator · Awarded by Fibrolamellar Cancer Foundation · 2016 - 2019Lumena PSC
Clinical TrialPrincipal Investigator · Awarded by Lumena Pharmaceuticals, Inc. · 2014 - 2017Characterizing Alcohol's Effects on Repair of Liver Injury
ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2012External Relationships
- Exact Sciences
- Gerson Lehrman Group
- GlaxoSmithKline
- Madrigal Pharmaceuticals
- Novo Nordisk
- Sirtex
- WebMD
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.